European Union: Pharma Regulators Heighten Scrutiny With New Theories of Harm and Increased Enforcement

Cleary Gottlieb partners Patrick Bock and Basak Arslan co-authored the article “European Union: Pharma Regulators Heighten Scrutiny With New Theories of Harm and Increased Enforcement,” published in GCR.

Patrick and Basak provide an overview of the European competition regulators’ enforcement activities in the pharmaceutical industry from 2018 to 2024. They identify the key trends and themes underlying the European Commission’s and national competition authorities’ investigations under article 101 and 102 of the Treaty on the Functioning of the European Union and the European Commission’s merger review decisions dating back to 2018.

Read the article (subscription required).